EICHOR
● Recruiting
An Early Clinical Study to Evaluate the Safety and Efficacy of CLDN18.2 CAR T Cell Injection in Subjects With CLDN18.2-Positive Advanced Malignant Solid Tumors
Condition: CLDN18.2 Positive Solid Tumors · Sponsor: Celest Therapeutics (Shanghai) Co., Ltd.
About this study
An open label, single/multiple dose exploratory clinical study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-claudin18.2 chimeric antigen receptor T cell in advanced solid tumor.
This description comes directly from the study's public registry record.
Talk to the study team
Huan Zhou · +86 13665527160 · zhouhuanbest@vip.163.com
Li Zhang · +86 18655125703 · 715011385@qq.com
Always discuss trial participation with your own doctor first.
Locations (1)
| The First Affiliated Hospital Of Anhui Medical University | Hefei, Anhui, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07680257